Home › Non-Muscle Invasive Bladder Cancer › NCT05672615

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With Bacillus Calmete-Guerin

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subjects with a pathologically confirmed non-muscle invasive bladder cancer
* Age ≥ 18 years old
* Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

* Patients that are not candidates for intravesical treatment due to the nature of their disease, such as variant histology or progressive disease after a prior course of intravesical treatment.
* Patients who are pregnant

About the study

The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study. Participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. The study team will also collect participant's medical history and clinical information. Participants will be asked to complete questionnaires and daily mood diaries.

What is being tested

• Questionnaires (other)
• Daily Mood Diaries (other)
• Urine Specimen Collection (other)
• Research Blood Draw (other)
• Utilize excess tissue from a standard of care procedure (other)

Sponsor: Johns Hopkins University · Participants: 42 · Started: Mar 21, 2023

Contact the study team

• Domani Rodriguez · Phone: 2026605561
• Armine Smith, MD · Phone: 202-660-5561

Official record on ClinicalTrials.gov — NCT05672615

Locations in the U.S.

Conditions

• Non-Muscle Invasive Bladder Cancer

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.